The Development of a Human Model of Respiratory Syncytial Virus Infection
Primary Purpose
Respiratory Syncytial Virus Infections, Respiratory Viral Infections
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
RSV A Memphis 37
Sponsored by
About this trial
This is an interventional basic science trial for Respiratory Syncytial Virus Infections focused on measuring Respiratory syncytial virus, RSV, Immunology, Viral infection, Bronchiolitis, Viral challenge, Viral lung disease
Eligibility Criteria
Inclusion Criteria:
- Healthy persons aged 18 to 55 years, able to give informed consent
Exclusion Criteria:
- Chronic respiratory disease (asthma, COPD, rhinitis, sinusitis) in adulthood
- Inhaled bronchodilator or steroid use within the last 12 months
- Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 6 months
- Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks
- Smoking in the past 6 months OR >5 pack-year lifetime history
- Subjects with allergic symptoms present at baseline
- Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease
- Subjects with known or suspected immune deficiency
- Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge
- History of frequent nose bleeds
- Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study
- Pregnant or breastfeeding women
Sites / Locations
- St. Mary's Hospital, Imperial College London, Norfolk Place,
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Viral Challenge
Arm Description
Outcomes
Primary Outcome Measures
Host response to RSV challenge
The host response to RSV challenge will be assessed daily for 14 days using methods such as symptom diaries, volume of nasal secretions, numbers of inflammatory cells in nasal mucus, and levels of chemical mediators in nasal fluids. This will be compared with that at baseline and at 28 days post challenge.
Secondary Outcome Measures
Full Information
NCT ID
NCT01349543
First Posted
May 5, 2011
Last Updated
June 3, 2015
Sponsor
Imperial College London
Collaborators
Wellcome Trust
1. Study Identification
Unique Protocol Identification Number
NCT01349543
Brief Title
The Development of a Human Model of Respiratory Syncytial Virus Infection
Official Title
The Development of a Human Model of Respiratory Syncytial Virus Infection
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
Wellcome Trust
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to understand the immune response (how the body fights infection) to Respiratory Syncytial Virus (RSV). This virus usually causes a simple 'common cold' illness in healthy adults, but can cause wheezing and lung problems in young infants and the elderly. The investigators want to understand why this is, in order to develop vaccines and treatments.
Participants will include 30-40 healthy adults age 18-55 years. Study procedures will include brief medical exams, breathing tests, a diary of symptoms, blood tests, samples of fluid (lavage) and cells from the nose, throat and lungs. All participants will receive the virus via drops in the nose. The duration of the study for all subjects will be 6 weeks.
Detailed Description
Bronchiolitis is the commonest cause of hospital admission in infants. It is caused by Respiratory Syncytial Virus(RSV), a virus that causes mild 'common colds' in adults, but can cause lung inflammation and difficulty breathing in infants and the elderly. In 2005, nearly 34 million cases in children <5 years occurred, resulting in 3.4 million hospital admissions,and around 120,000 deaths. There is no vaccine, and some previous vaccines actually made the disease worse.
The investigators have been trying to understand why for 40 years. Advances in immunology have given us a completely different way of looking at inflammation: rather than studying what causes it, the investigators now want to know what regulates it. Much of what the investigators know about how what causes and regulates inflammation has come from studies of animals, however, these do not exactly predict what happens in man.
The investigators therefore plan to infect healthy adult volunteers with RSV, and observe what happens in humans after RSV infection. The investigators will collect samples of blood, fluid and cells from the nose, throat, and lungs, and a diary of symptoms over four weeks. The investigators will analyse the blood, fluid, and cells to determine the important mechanisms that regulate inflammation in human RSV infection.
Studies like this have been conducted previously with no severe side effects. The investigators anticipate that the discoveries made in this research project will help us achieve a better understanding of what causes and regulates inflammation in RSV so that the investigators can learn ways to control it, with the aim of developing vaccines and treatments.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Syncytial Virus Infections, Respiratory Viral Infections
Keywords
Respiratory syncytial virus, RSV, Immunology, Viral infection, Bronchiolitis, Viral challenge, Viral lung disease
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Viral Challenge
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
RSV A Memphis 37
Other Intervention Name(s)
M37
Intervention Description
Intranasal administration
Primary Outcome Measure Information:
Title
Host response to RSV challenge
Description
The host response to RSV challenge will be assessed daily for 14 days using methods such as symptom diaries, volume of nasal secretions, numbers of inflammatory cells in nasal mucus, and levels of chemical mediators in nasal fluids. This will be compared with that at baseline and at 28 days post challenge.
Time Frame
Prior to and 0-28 days post challenge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy persons aged 18 to 55 years, able to give informed consent
Exclusion Criteria:
Chronic respiratory disease (asthma, COPD, rhinitis, sinusitis) in adulthood
Inhaled bronchodilator or steroid use within the last 12 months
Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 6 months
Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks
Smoking in the past 6 months OR >5 pack-year lifetime history
Subjects with allergic symptoms present at baseline
Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease
Subjects with known or suspected immune deficiency
Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge
History of frequent nose bleeds
Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study
Pregnant or breastfeeding women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Openshaw
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Mary's Hospital, Imperial College London, Norfolk Place,
City
London
ZIP/Postal Code
W2 1PG
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
The Development of a Human Model of Respiratory Syncytial Virus Infection
We'll reach out to this number within 24 hrs